Janus Kinase Inhibitors: all 1,428 studies that test it

Page 5 of 15. Open to participants first (328), then studies with results posted, then the rest; newest registration first within each.

• The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic DermatitisCompletedNCT04839380Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With VitiligoCompletedNCT04818346Phase 2Results posted
• Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell CarcinomaTerminatedNCT04807777Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)CompletedNCT04797650Phase 3Results posted
• A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia AreataCompletedNCT04784533Phase 2Results posted
• Adaptive COVID-19 Treatment Trial 4 (ACTT-4)CompletedNCT04640168Phase 3Results posted
• Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate CancerTerminatedNCT04635059Phase 2Results posted
• To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)CompletedNCT04629508Phase 2Results posted
• A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative ColitisCompletedNCT04613518Phase 2Results posted
• Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy ParticipantsCompletedNCT04608344Phase 1Results posted
• Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic DermatitisCompletedNCT04598269Phase 2Results posted
• Tofacitinib For Treatment Of Chronic PouchitisTerminatedNCT04580277Phase 2Results posted
• Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe ThrombocytopeniaTerminatedNCT04543279Phase 2Results posted
• Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With VitiligoCompletedNCT04530344Phase 3Results posted
• Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1)CompletedNCT04518995Phase 3Results posted
• PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATATerminatedNCT04517864Phase 2Results posted
• A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGSTerminatedNCT04517253Phase 2/3Results posted
• Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's SyndromeActive, not recruitingNCT04496960Phase 1/2Results posted
• Ruxolitinib Cream in the Treatment of Cutaneous Necrobiosis LipoidicaCompletedNCT04492618Phase 2Results posted
• To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis SuppurativaCompletedNCT04476043Phase 2Results posted
• INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative DisordersCompletedNCT04455841Phase 1/2Results posted
• A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease StateCompletedNCT04451772Phase 2Results posted
• Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHDTerminatedNCT04446182Phase 2Results posted
• A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease SymptomsCompletedNCT04430855Phase 2Results posted
• A Study of Baricitinib (LY3009104) in Participants With COVID-19CompletedNCT04421027Phase 3Results posted
• Tofacitinib for Treatment of Moderate COVID-19TerminatedNCT04415151Phase 2Results posted
• Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa TreatmentTerminatedNCT04414514Phase 2Results posted
• TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATECompletedNCT04413617Phase 2Results posted
• PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without CancerTerminatedNCT04404361Phase 2Results posted
• TD-0903 for ALI Associated With COVID-19CompletedNCT04402866Phase 2Results posted
• Adaptive COVID-19 Treatment Trial 2 (ACTT-2)CompletedNCT04401579Phase 3Results posted
• Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)TerminatedNCT04377620Phase 3Results posted
• Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRSCompletedNCT04374149Phase 2Results posted
• Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine StormCompletedNCT04362137Phase 3Results posted
• Itacitinib in Advanced Hepatocellular CarcinomaCompletedNCT04358185Phase 1Results posted
• Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical TherapyCompletedNCT04345367Phase 3Results posted
• Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 MutationCompletedNCT04281498Phase 2Results posted
• Renal Impairment Study of PF-06700841CompletedNCT04260464Phase 1Results posted
• Tofacitinib for Immune Skin Conditions in Down SyndromeCompletedNCT04246372Phase 2Results posted
• A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD)TerminatedNCT04200365Phase 2Results posted
• Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic DermatitisCompletedNCT04195698Phase 3Results posted
• A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)CompletedNCT04173494Phase 3Results posted
• A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial SpondyloarthritisCompletedNCT04169373Phase 3Results posted
• An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South KoreaCompletedNCT04167462Phase 3Results posted
• A Phase II Study in Adult Patients With Moderate to Severe Atopic DermatitisCompletedNCT04162899Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD TherapyTerminatedNCT04115839Phase 3Results posted
• Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD TherapyTerminatedNCT04115748Phase 3Results posted
• Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)CompletedNCT04105010Phase 1/2Results posted
• A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis SuppurativaCompletedNCT04092452Phase 2Results posted
• A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive UveitisActive, not recruitingNCT04088409Phase 3Results posted
• A Study of Baricitinib in Participants With Rheumatoid ArthritisCompletedNCT04086745Phase 4Results posted
• Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)CompletedNCT04057573Phase 3Results posted
• Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDSCompletedNCT04055844Phase 2Results posted
• Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)CompletedNCT04052425Phase 3Results posted
• A Renal Impairment Study for PF-06651600TerminatedNCT04037865Phase 1Results posted
• A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy VolunteersCompletedNCT04016077Phase 1Results posted
• Long-Term PF-06651600 for the Treatment of Alopecia AreataCompletedNCT04006457Phase 3Results posted
• Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung TransplantationTerminatedNCT03978637Phase 1/2Results posted
• A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)CompletedNCT03978520Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic ArthritisCompletedNCT03963401Phase 2Results posted
• Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.TerminatedNCT03958955Phase 2Results posted
• Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host DiseaseActive, not recruitingNCT03954236Phase 2Results posted
• A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic DermatitisCompletedNCT03952559Phase 3Results posted
• An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With RuxolitinibCompletedNCT03952039Phase 3Results posted
• An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus NephritisTerminatedNCT03943147Phase 2Results posted
• Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia AreataCompletedNCT03941548Phase 2Results posted
• Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative ColitisCompletedNCT03934216Phase 2Results posted
• Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial SpondyloarthritisCompletedNCT03926195Phase 2Results posted
• An Investigational Study to Evaluate Experimental Medication BMS-986165 in Japanese Participants With Moderate-to-Severe PsoriasisCompletedNCT03924427Phase 3Results posted
• JAK Inhibitor Treatment in AGSCompletedNCT03921554Phase 2Results posted
• Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus ErythematosusCompletedNCT03920267Phase 2Results posted
• TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) StudyTerminatedNCT03920254Phase 2/3Results posted
• A Study of Baricitinib (LY3009104) in Participants With Rheumatoid ArthritisCompletedNCT03915964Phase 4Results posted
• Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic DermatitisCompletedNCT03915496Phase 2Results posted
• Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic DermatitisCompletedNCT03903822Phase 2Results posted
• A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia AreataCompletedNCT03899259Phase 3Results posted
• A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque PsoriasisCompletedNCT03895372Phase 2Results posted
• Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)CompletedNCT03881059Phase 2Results posted
• Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative NeoplasmsTerminatedNCT03878199Phase 1/2Results posted
• Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In PsoriasisCompletedNCT03850483Phase 2Results posted
• Itacitinib for Low Risk GVHDCompletedNCT03846479Phase 2Results posted
• A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)CompletedNCT03845517Phase 2Results posted
• A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)TerminatedNCT03843125Phase 3Results posted
• A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With UpadacitinibTerminatedNCT03823378Phase 2Results posted
• Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia AreataCompletedNCT03811912Phase 2Results posted
• Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia AreataCompletedNCT03800979Phase 4Results posted
• JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic DermatitisCompletedNCT03796676Phase 3Results posted
• Study of PF 04965842 Effect on MATE1/2K Activity in Healthy ParticipantsCompletedNCT03796182Phase 1Results posted
• Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent SarcoidosisCompletedNCT03793439Phase 1Results posted
• Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell TransplantCompletedNCT03774082Phase 2Results posted
• A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic ArthritisCompletedNCT03773978Phase 3Results posted
• LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple MyelomaCompletedNCT03773107Phase 1/2Results posted
• ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)TerminatedNCT03759340Phase 2Results posted
• Efficacy & Safety of TD-1473 in Ulcerative ColitisTerminatedNCT03758443Phase 2/3Results posted
• A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With RuxolitinibTerminatedNCT03755518Phase 3Results posted
• Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell TransplantationCompletedNCT03755414Phase 1Results posted
• TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic DermatitisCompletedNCT03745651Phase 3Results posted
• Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic DermatitisCompletedNCT03745638Phase 3Results posted
• A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCATerminatedNCT03742973Phase 2Results posted
• A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic DermatitisCompletedNCT03738397Phase 3Results posted

← Janus Kinase Inhibitors overview